Latuda

RSS

lurasidone

Authorised
This medicine is authorised for use in the European Union.

Overview

Latuda is a medicine that is used to treat patients from 13 years of age with schizophrenia, a mental illness with symptoms that include disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).

Latuda contains the active substance lurasidone.

This EPAR was last updated on 17/03/2022

Authorisation details

Product details
Name
Latuda
Agency product number
EMEA/H/C/002713
Active substance
lurasidone
International non-proprietary name (INN) or common name
lurasidone
Therapeutic area (MeSH)
Schizophrenia
Anatomical therapeutic chemical (ATC) code
N05AE05
Publication details
Marketing-authorisation holder
Aziende Chimiche Riunite Angelini Francesco S.p.A.
Revision
25
Date of issue of marketing authorisation valid throughout the European Union
21/03/2014
Contact address
Viale Amelia 70
00181
Roma
Italy

Product information

10/03/2022 Latuda - EMEA/H/C/002713 - II/0037

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Treatment of schizophrenia in adults aged 18 years and over.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
2 ratings